Whose endo regularly suggests you get a GlycoMark test? Wait, better question: who has the slightest idea what constitutes “in range” for the GlycoMark test, or what the heck you’re supposed to do with the results?
Yeah, I thought so… me neither.
We’ve mentioned GlycoMark a few times here at the ‘Mine, but when it recently came up in conversation, our team basically all looked at each other and shrugged. This year’s ADA Conference seemed…
As we mark the Fourth of July here in the U.S.A., we thought this would be a great time to explore the idea of freedom as it relates to our dependence on diabetes apparatus.
Admit it: As free as we can sometimes feel about the flexibility modern diabetes technology provides, our devices also serve as a constant reminder of our illness, shadowing us wherever we go. Most of us, at one time or another, have…
Just a few short years ago, no one could have envisioned the Diabetes Online Community would become what it is today. And be moving in the collaborative direction it’s going…
Seriously, some likely would have laughed at the idea while shaking their heads in disbelief!
It used to be “Us versus Them,” in terms of the relationship between Pharma and people with diabetes (PWDs). There was little interaction; we didn’t know them and they didn’t…
Sometimes, diabetes science confuses me.
Let’s take the news of an emerging class of diabetes drugs (type 2-focused) that apparently do something we’ve always thought was bad… but it’s actually not.
Sodium-glucose transporter (SGLT-2) inhibitors increase insulin production and effectiveness and stop the liver from producing too much glucose. Basically, they work by spilling glucose over into the urine which leads to less sugar in your bloodstream. The effect: lower BGs and A1Cs.
Sure, it…
Hmmm, I wonder if this will catch on…
Thanks to our guest, Meredith Gruebbel, a type 1 PWD, who works in Louisville, KY, as graphic designer and blogs about her life with diabetes at With a Side of Insulin.
…